Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.